SCYNEXIS, Inc.: SCYNEXIS, Inc. Receives Preclinical Milestone Payment in Collaboration With Merck
SCYNEXIS, Inc. Receives Preclinical Milestone Payment in Collaboration With Merck
RESEARCH TRIANGLE PARK, NC — (MARKET WIRE) — January 09, 2007 — SCYNEXIS, Inc. today announcedthat it has
earned a $1 million payment from Merck & Co., Inc. for meetingcertain preclinical milestones in the companies’ collaboration to developnovel antifungal agents.
“Merck and SCYNEXIS have collaborated for several years to discover anddevelop novel antifungal agents,” said Merv Turner, Ph.D., Merck seniorvice president, Worldwide Licensing and External Research. “We are pleasedwith the progress we’ve made to date and with SCYNEXIS’ contributions toour collaboration.”
“SCYNEXIS is pleased to celebrate the success in reaching an importantmilestone in this project with our valued partner Merck,” noted YvesRibeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. “Thismilestone was achieved through a true and open partnership.”
About SCYNEXIS
SCYNEXIS is a chemistry-focused drug discovery and development company withits headquarters located in Research Triangle Park, North Carolina.SCYNEXS’ goal, from concept to clinic, is to deliver effective andinnovative drug pipeline solutions to our pharmaceutical partners.SCYNEXIS’ research teams integrate computational chemistry, medicinalchemistry, bioanalysis and process chemistry. SCYNEXIS teams use powerful,proprietary technologies such as the HEOS® Software Suite,MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to optimize leadmolecules for candidate selection. SCYNEXIS process chemistry andbioanalytical departments operate under current GMP/GLP guidelines and haveestablished a strong track record of success. SCYNEXIS tailors its teamsto be especially effective in moving customer projects from the discoveryphase to clinical proof of concept. SCYNEXIS’ website is located atwww.scynexis.com.
Popularity: 1% [?]
